US Patent

US9629852 — Ophthalmic composition comprising a prostaglandin

Formulation · Assigned to Sun Pharma Advanced Research Co Ltd · Expires 2029-09-12 · 3y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a pharmaceutical composition for ophthalmic use that includes one or more prostaglandin derivatives or salts and a stabilizing amount of polyethylene glycol hydroxystearate.

USPTO Abstract

The present invention relates to a pharmaceutical composition suitable for ophthalmic use comprising one or more prostaglandin derivatives or salts, a stabilizing amount of polyethylene glycol hydroxystearate and pharmaceutically acceptable vehicle.

Drugs covered by this patent

Patent Metadata

Patent number
US9629852
Jurisdiction
US
Classification
Formulation
Expires
2029-09-12
Drug substance claim
No
Drug product claim
Yes
Assignee
Sun Pharma Advanced Research Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.